Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT
Status:
Active, not recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
Acute leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia
(ALL), is the subtype of leukemia with the highest mortality, and leukemia relapse caused by
the protective bone marrow microenvironment is the main cause of treatment failure. The
chemokine receptor CXCR4 plays a crucial role in the homing and settling of leukemia cells
into the bone marrow. Preclinical study of the investigators demonstrates that CXCR4 blockade
can mobilize leukemia cells from their protective bone marrow microenvironment to periphery,
thereby significantly enhancing the killing effect of allogeneic lymphocytes against leukemia
cells. This study aims to preliminarily evaluate the efficacy and safety of donor lymphocyte
infusion (DLI) plus CXCR4 antagonist plerixafor in the treatment of relapsed acute leukemia
patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT) through a
prospective single arm study. The results may preliminarily confirm the effectiveness and
safety of DLI combined with plerixafor in the treatment of recurrent acute leukemia patients
after allo-HSCT, providing a reference basis for further research.